Papillon Therapeutics
Business Services · 1-10 Employees
View Company Info for Free
Overview
Website
www.papillon-tx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Papillon Therapeutics
Papillon Therapeutics specializes in developing gene-edited stem cell therapies aimed at treating Friedreich's ataxia and other multi-systemic genetic diseases. The company focuses on delivering transformative medicines that provide cures from within the body. Their innovative approach targets complex genetic conditions, making them a key player in the field of genetic therapies. Intended clients include patients suffering from these specific genetic disorders and healthcare providers seeking advanced treatment options.Explore more
Papillon Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Papillon Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Papillon Therapeutics launches new products
Funding: Get notified immidiatlly once Papillon Therapeutics has new funding data
Click to see if Papillon Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Papillon Therapeutics recently announced quarterly report
Papillon Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Papillon Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Papillon Therapeutics
Check if Papillon Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Papillon Therapeutics
Compare insights from companies similar to Papillon Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Papillon Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Papillon Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Papillon Therapeutics.
Papillon Therapeutics News & Media
Papillon Therapeutics Receives Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for PPL-001 for the Treatment of Friedreich's Ataxia
SAN DIEGO--(BUSINESS WIRE)--Papillon Therapeutics Inc., a clinical-stage biotechnology company advancing a pipeline of multi-systemic genetic medicines directed at the underlying causes of inherited disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Papillon’s PPL-001, an experimental treatment for Friedreich's ataxia. PPL-001 has previously received Orphan Drug designation. “We are thrilled to receive Rare Pediatric DiseaPapillon Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for PPL-002 for the Treatment of Danon Disease
SAN DIEGO--(BUSINESS WIRE)--Papillon Therapeutics Inc., a clinical-stage biotechnology company advancing a pipeline of multi-systemic genetic medicines directed at the underlying causes of inherited disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Papillon’s PPL-002, an experimental treatment for Danon disease. “We are grateful that the FDA has granted Orphan Drug Designation to PPL-002, which marks the second designation for PapilPapillon Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for PPL-001 for the Treatment of Friedreich's Ataxia
SAN DIEGO--(BUSINESS WIRE)--Papillon Therapeutics Inc. received Orphan Drug Designation to PPL-001, an experimental gene therapy for Friedreich's ataxiaNuFund Venture Group Invests in Papillon Therapeutics to Advance Multi-Systemic Genetic Medicines
NuFund Venture Group (‘NuFund’), California-based investment fund, is excited to declare its latest investment in Papillon Therapeutics, Inc., (‘Papillon’). Papillon... Read More The post NuFund Venture Group Invests in Papillon Therapeutics to Advance Multi-Systemic Genetic Medicines appeared first on citybiz.
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Papillon Therapeutics
Sign Up For FreeTo access detailed company insights
Papillon Therapeutics specializes in developing gene-edited stem cell therapies aimed at treating Friedreich's ataxia and other multi-systemic genetic diseases. The company focuses on delivering transformative medicines that provide cures from within the body. Their innovative approach targets complex genetic conditions, making them a key player in... Read More
